KYNTRA BIO, INC.

Kyntra Bio announced additional post hoc analysis data from the Phase 3 MATTERHORN trial for roxadustat, demonstrating durable and clinically meaningful improvements in transfusion independence (TI) for patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB). The data showed similar TI rates in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) disease, an important finding given limited options for RS- patients. The company is finalizing the pivotal Phase 3 trial protocol based on FDA feedback and expects to initiate it in the second half of 2026, with these findings to be presented at the EHA Congress 2026.

Kyntra Bio, Inc. announced it received the final $4.0 million holdback payment from AstraZeneca Treasury Limited on June 2, 2026. This payment completes all owed amounts under the Share Purchase Agreement related to the sale of Kyntra Bio's China operations, which closed on August 29, 2025. The total consideration for the sale was approximately $220 million, with $210 million paid at closing and the remaining $10.0 million subject to two holdbacks, both of which have now been fully satisfied.

Kyntra Bio, Inc. reported a net loss of $15.2 million for the first quarter of 2026, a significant change from a net income of $4.6 million in the prior year. Total revenue increased by 36% to $3.7 million, driven by higher drug product revenue, but was offset by a substantial increase in cost of goods sold and a shift to net cash used in operating activities. The company also noted its rebranding from FibroGen, Inc. in January 2026 and its continued focus on oncology and rare disease assets, including advancing its FG-3246 and roxadustat programs.

Kyntra Bio reported first-quarter 2026 financial results, with total revenue increasing to $3.7 million from $2.7 million year-over-year. The net loss from continuing operations improved to $15.1 million, or $3.74 per share, compared to a $16.8 million loss in the prior year. The company also provided positive business updates, including progress in its Phase 2 trial for FG-3246 in mCRPC, with interim analysis expected in Q4 2026, and finalization of the Phase 3 trial protocol for roxadustat following FDA feedback, targeting a H2 2026 initiation. Kyntra Bio maintains a strong cash position of $100.3 million, providing a cash runway into 2028.

Kyntra Bio reported its first quarter 2026 financial results, showing increased revenue and a reduced net loss compared to the prior year. The company also provided positive updates on its pipeline, with the Phase 2 trial of FG-3246 progressing towards an interim analysis in Q4 2026 and the pivotal Phase 3 trial protocol for roxadustat being finalized with FDA feedback for a 2H 2026 initiation. Kyntra Bio maintains a strong financial position with $100.3 million in cash and equivalents, providing a runway into 2028.

Kyntra Bio, Inc. announced it will release its first quarter 2026 financial results on Monday, May 11, after market close. The company will also host a conference call and webcast on the same day at 5:00 PM Eastern Time to discuss its corporate and financial performance, followed by a live Q&A session. Kyntra Bio is a biopharmaceutical company focused on oncology and rare disease, with key programs including Roxadustat and FG-3246.

Kyntra Bio, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on June 12, 2026. Stockholders will vote on the election of Class III director nominee Michael Kauffman, M.D., Ph.D., an advisory resolution on named executive officer compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026. The record date for voting is April 16, 2026.

KYNTRA BIO, INC. (KYNB) announced it received a notice from the Nasdaq Listing Qualifications Staff on April 2, 2026, indicating non-compliance with the Nasdaq Global Select Market's continued listing requirement of $50 million in total assets and total revenue. This non-compliance stems from the reclassification of FibroGen International's revenue as held for sale in discontinued operations for 2024 and 2025. The company has 45 days, until May 18, 2026, to submit a plan to regain compliance, with a potential extension of up to 180 days until September 29, 2026. The notice does not immediately affect the stock's listing, and KYNB may also consider transferring its securities to the Nasdaq Capital Market.